Elie Abed is an Endocrinology/Metabolic physician affiliated with University of Oklahoma Health Sciences Center. OpenAlex indexes 40 publications with 978 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9228 S Mingo Rd Ste 200
Tulsa, OK 74133
Telephone
918-592-0999Registry record last updated 10 Jan 2019.
Industry payments
43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202517 payments
- Amneal Pharmaceuticals LLCProgram year202510 payments
- Amgen Inc.Program year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
44.9%RANK Ligand Inhibitor44.9%Denosumab99%Prolia1%Part D + Part B≥67 patientsMetabolism & gastrointestinal
31.2%GLP-1 receptor agonist10.4%Ozempic44%Mounjaro37%Trulicity18%Rybelsus2%Part D<11 patientsInsulin Analog9.6%Lantus Solostar18%Tresiba Flextouch U-20015%Novolog Flexpen13%Humalog Kwikpen U-1009%Toujeo Max Solostar8%Tresiba Flextouch U-1007%Lyumjev Kwikpen U-1006%Fiasp Flextouch4%Insulin Lispro Kwikpen U-1003%Toujeo Solostar3%Basaglar Kwikpen U-1003%Soliqua 100-333%Insulin Lispro2%Humalog2%Novolog2%Humalog Kwikpen U-2002%Levemir Flexpen1%Lantus1%Part D<11 patients+ 9 more classes in this area
Hormonal (systemic)
10.7%l-Thyroxine8.2%Levothyroxine Sodium76%Synthroid24%Part D≥236 patientsThyroid Hormone Synthesis Inhibitor1.4%Methimazole100%Part D≥56 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing
Journal of Pediatric Endocrinology and Metabolism
2019 - Beneficial effect of resveratrol on phenotypic features and activity of osteoarthritic osteoblasts
Arthritis Research & Therapy
2017 - Carboxylated and uncarboxylated osteocalcin levels are not linked with insulin resistance in osteoarthritis patients
Osteoarthritis and Cartilage
2017 - Sirtuins as Markers of Bone Disease: A Focus on Osteoarthritis and Osteoporosis
Biomarkers in disease
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Ira Targoff, MD
University of Oklahoma Health Sciences Center
Harold Burkhart, MD
University of Oklahoma Health Sciences Center
Steven Chernausek, MD
University of Oklahoma Health Sciences Center
Udho Thadani, MD
University of Oklahoma Health Sciences Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”